18889881171
Kalkine 0
countryflagUS

Annexon Inc

Healthcare US ANNX

2.4USD
-0.04(1.64%)

Last update at 2025-06-17T16:59:00Z

Day Range

2.372.48
LowHigh

52 Week Range

2.348.40
LowHigh

Fundamentals

  • Previous Close 2.44
  • Market Cap528.71M
  • Volume339686
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-124.79100M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -141.94700M -130.32300M -63.41200M -37.17900M -18.30300M
Minority interest - - - - -
Net income -138.29500M -127.79200M -62.74500M -37.18300M -18.30400M
Selling general administrative 33.10M 30.65M 14.20M 7.99M 3.62M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 2.11M 2.14M 0.67M 0.49M 0.49M
Ebit -147.70500M -132.85400M -64.13600M -32.51800M -19.14700M
Ebitda -145.59900M -130.71300M -63.46900M -32.02500M -18.65900M
Depreciation and amortization 2.11M 2.14M 0.67M 0.49M 0.49M
Non operating income net other - - 0.06M - -
Operating income -145.59900M -130.71300M -63.46900M -32.51800M -19.14700M
Other operating expenses 145.60M 130.71M 63.47M 32.52M 19.15M
Interest expense 3.65M 2.14M 0.00000M 4.66M 0.00000M
Tax provision - 0.00000M 0.00000M 0.00400M 0.00100M
Interest income 3.65M 0.39M - 0.01M 0.04M
Net interest income 3.65M 0.39M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.65200M -2.53100M -0.66700M 0.00400M 0.00100M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 145.60M 130.71M 63.47M 32.52M 19.15M
Cost of revenue - - - - -
Total other income expense net 3.65M 0.39M 0.06M -4.66100M 0.84M
Discontinued operations - - - - -
Net income from continuing ops -145.59900M -130.71300M -63.41200M -37.18300M -18.30400M
Net income applicable to common shares -141.94700M -130.32300M -70.33600M -38.27800M -18.48000M
Preferred stock and other adjustments - - 0.70M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 297.67M 285.10M 287.04M 355.95M 49.90M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.14M 5.44M 4.98M 2.81M 1.40M
Total liab 47.12M 53.90M 55.13M 11.67M 6.37M
Total stockholder equity 250.56M 231.19M 231.91M 344.28M 43.53M
Deferred long term liab - - - 1.05M 2.30M
Other current liab 10.28M 13.63M 0.14M 6.89M 2.56M
Common stock 0.08M 0.05M 0.04M 0.04M 0.00400M
Capital stock 0.08M 0.05M 0.04M 0.04M 143.99M
Retained earnings -572.49900M -438.26200M -296.31500M -165.99200M -102.58000M
Other liab - - - 1.05M 1.44M
Good will - - - - -
Other assets 0.00000M 1.03M 1.17M - 2.35M
Cash 225.11M 140.02M 74.84M 268.56M 43.93M
Cash and equivalents - - - - -
Total current liabilities 17.93M 22.36M 21.74M 10.62M 4.93M
Current deferred revenue - - 9.25M - -
Net debt -193.75500M -107.16200M -40.25400M -268.56500M -43.93100M
Short term debt 2.17M 1.32M 1.20M - -
Short long term debt - - - - -
Short long term debt total 31.36M 32.86M 34.59M - -
Other stockholder equity 823.03M 669.78M 528.37M 154.36M 2.20M
Property plant equipment - 16.84M 38.18M 1.94M 2.14M
Total current assets 263.86M 248.10M 247.69M 354.01M 45.41M
Long term investments - - - - -
Net tangible assets - 231.19M 231.91M 344.28M -100.45400M
Short term investments 34.61M 102.64M 167.87M 82.64M -
Net receivables - - - 0.00300M 0.08M
Long term debt - - - - -
Inventory - - - -0.00300M -
Accounts payable 5.49M 7.42M 11.15M 3.73M 2.37M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.05200M -0.37200M -0.18000M -0.07700M -0.08000M
Additional paid in capital - - - - -
Common stock total equity - 0.05M 0.04M 0.04M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - -438.26200M -296.31500M -165.99200M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.03M 1.03M 1.17M - 2.35M
Deferred long term asset charges - - - - -
Non current assets total 33.81M 37.00M 39.35M 1.94M 4.49M
Capital lease obligations 31.36M 32.86M 34.59M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 64.97M -86.58200M -83.16400M -0.26700M -0.01700M
Change to liabilities 5.93M 3.86M 1.51M 0.93M -0.25300M
Total cashflows from investing activities 58.44M -88.23600M -83.16400M -0.26700M -0.01700M
Net borrowings - - - - -
Total cash from financing activities 122.91M 1.79M 360.88M 28.39M 58.46M
Change to operating activities 4.03M -0.57500M 3.20M -0.30600M 0.73M
Net income -141.94700M -130.32300M -63.41200M -37.18300M -18.30400M
Change in cash 65.04M -192.55600M 224.63M -0.24400M 41.21M
Begin period cash flow 76.01M 268.56M 43.93M 44.17M 2.97M
End period cash flow 141.05M 76.01M 268.56M 43.93M 44.17M
Total cash from operating activities -116.30900M -106.11000M -53.08700M -28.35800M -17.19000M
Issuance of capital stock 130.48M 0.00000M 369.02M 30.00M 58.34M
Depreciation 2.11M 2.14M 0.67M 0.49M 0.49M
Other cashflows from investing activities - - - - -
Dividends paid - - -102.52200M - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 121.40M 1.79M -5.19300M 30.00M 58.46M
Other cashflows from financing activities -7.56800M 1.79M 202.07M 28.39M 58.46M
Change to netincome 18.52M 18.79M 4.94M 7.71M 0.15M
Capital expenditures 6.53M 1.65M 0.46M 0.27M 0.02M
Change receivables - - - - -
Cash flows other operating -0.98900M -0.21400M -1.60000M - -
Exchange rate changes - - 0.00900M - -
Cash and cash equivalents changes 65.04M -192.55100M 224.63M - -
Change in working capital 3.74M 3.28M 4.72M 0.62M 0.48M
Stock based compensation 18.52M 16.26M 4.89M 2.04M 0.41M
Other non cash items 1.28M 1.27M 0.05M 5.67M -0.26000M
Free cash flow -122.83500M -107.76400M -53.55100M -28.62500M -17.20700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ANNX
Annexon Inc		 -0.04 1.64% 2.40 - - - 1.64 -2.4694
NVO
Novo Nordisk A/S		 -2.38 3.09% 74.64 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.16 4.04% 75.15 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.28 0.51% 448.63 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -3.845 0.74% 518.84 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Annexon Inc

1400 Sierra Point Parkway, Brisbane, CA, United States, 94005

Key Executives

Name Title Year Born
Mr. Douglas Love J.D., Esq. CEO, Pres & Director 1968
Dr. Larry C. Mattheakis Ph.D. Exec. VP & Chief Scientific Officer 1957
Dr. Ted Yednock Ph.D. Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board 1958
Dr. Arnon Rosenthal Ph.D. Founder 1956
Ms. Jennifer Lew Exec. VP & CFO 1973
Miriam Mason Sr. VP of Corp. Communications NA
Mr. Michael Overdorf M.B.A. Exec. VP & Chief Bus. Officer 1970
Henk-Andre Kroon M.D. Sr. VP of Translational Medicine NA
Mirella Villa Del Toro Sec. NA
Mr. Douglas Love Esq., J.D. CEO, President & Director 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.